---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Pharmacokinetics"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: Pharmacokinetics. Topics: Phase 1 bridging study: aroxybutynin 2.3 mg versus racemic oxybutynin 5 mg (APC-001); Phase 1: components given alone and in combination, and time to maximum concentration (APC-001 and APC-002); Metabolic pathways of the two components; Atomoxetine label: pharmacokinetic parameters by CYP2D6 metabolizer type; 3 further topics. 7 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description/pharmacokinetics"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Pharmacokinetics

<a id="heading-2.1.2.6.3"></a>

## 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

### Phase 1 bridging study: aroxybutynin 2.3 mg versus racemic oxybutynin 5 mg (APC-001)

> “The trial was a single dose two-way crossover trial in 24 subjects comparing 2.3mg aroxybutynin to 5mg oxybutynin. The trial found that the drug levels of aroxybutynin were consistent with levels seen with racemic oxybutynin. The trial served as a pharmacokinetic bridging study to oxybutynin as a reference listed drug for aroxybutynin.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.2.6.3-2"></a>

### Phase 1: components given alone and in combination, and time to maximum concentration (APC-001 and APC-002)

> “The Phase 1 trials overall established that drug levels of aroxybutynin (APC-001) and atomoxetine (APC-002) were not different whether administered alone or in combination. Both aroxybutynin and atomoxetine were absorbed rapidly with maximum concentrations being observed in one to four hours, which is considered appropriate for a combination therapeutic administered at bedtime and acting during the night.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.2.6.3-3"></a>

### Metabolic pathways of the two components

> “Atomoxetine is metabolized by CYP2D6 and aroxybutynin by CYP3A4, and consequently, strong pharmacologic inhibitors of these metabolic enzymes are not allowed as concomitant therapy.”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

<a id="topic-2.1.2.6.3-4"></a>

### Atomoxetine label: pharmacokinetic parameters by CYP2D6 metabolizer type

| Parameter | Other CYP2D6 metabolizer types | CYP2D6 poor metabolizers |
| --- | --- | --- |
| Accumulation | “1.1-fold” | “3.3-fold” |
| Absolute bioavailability | “63%” | “94%” |
| Median time to maximum concentration | “1 hour” | “2.5 hour” |
| Atomoxetine half-life | “5.2 hours” | “21.6 hours” |
| Atomoxetine apparent oral clearance | “0.35 L/hr/kg” | “0.03 L/hr/kg” |
| Primary metabolic pathways | “CYP2D6” | “Other CYP enzymes” |

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.6.3-5"></a>

### Atomoxetine label: food effect, distribution, excretion, and exposure in CYP2D6 poor metabolizers

> “AUC: Unchanged; Cmax: Decreased 37%; Tmax: Delayed 3 hours”
> “Protein Binding 98%”
> “Less than 3% as unchanged drug”
> “Atomoxetine AUC was approximately 10-fold higher and atomoxetine Css, max was approximately 5-fold higher in CYP2D6 poor metabolizers compared to other CYP2D6 metabolizer types”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.6.3-6"></a>

### Oxybutynin label: R-oxybutynin and S-oxybutynin after a single 10 mg extended-release dose

| Parameter | R-oxybutynin | S-oxybutynin |
| --- | --- | --- |
| Cmax (ng/mL), mean (SD) | “1.0 (0.6)” | “1.8 (1.0)” |
| Tmax (h), mean (SD) | “12.7 (5.4)” | “11.8 (5.3)” |
| Half-life (h), mean (SD) | “13.2 (6.2)” | “12.4 (6.1)” |
| AUCinf (ng•h/mL), mean (SD) | “21.3 (12.2)” | “39.5 (21.2)” |

Source: [Janssen DITROPAN XL prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020897s038lbl.pdf)

<a id="topic-2.1.2.6.3-7"></a>

### Oxybutynin label: distribution, metabolism, and excretion

> “Both enantiomers of oxybutynin are highly bound (>99%) to plasma proteins.”
> “Oxybutynin is metabolized primarily by the cytochrome P450 enzyme systems, particularly CYP3A4 found mostly in the liver and gut wall. Its metabolic products include phenylcyclohexylglycolic acid, which is pharmacologically inactive, and desethyloxybutynin, which is pharmacologically active.”
> “Oxybutynin is extensively metabolized by the liver, with less than 0.1% of the administered dose excreted unchanged in the urine.”
> “The rate and extent of absorption and metabolism of oxybutynin are similar under fed and fasted conditions.”

Source: [Janssen DITROPAN XL prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020897s038lbl.pdf)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
